Edward B. Garon, MD

Articles

Dr. Garon on the Role of Trastuzumab Deruxtecan in Lung Cancer

August 27th 2020

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.

Dr. Garon on Unique Challenges of COVID-19 in Lung Cancer

August 21st 2020

Edward B. Garon, MD, discusses unique challenges of the coronavirus disease 2019 in lung cancer.

Dr. Garon on the Expanding Treatment Landscape in Lung Cancer

August 21st 2020

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

Dr. Garon on Immunotherapy in Stage III Unresectable NSCLC

March 14th 2019

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the promise of immunotherapy in the treatment of patients with stage III unresectable non–small cell lung cancer.

Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC

January 26th 2019

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

Dr. Garon Discusses Driver Mutations in SCLC

October 10th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses driver mutations in small cell lung cancer.

Dr. Garon Discusses Pegilodecakin Plus a PD-1 Inhibitor in NSCLC

June 28th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the combination of pegilodecakin (AM0010) and a PD-1 inhibitor in patients with advanced non–small cell lung cancer.

Dr. Garon on Immunotherapy Combinations in NSCLC

April 30th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses immunotherapy combinations in non–small cell lung cancer.

Dr. Garon Discusses the CheckMate-384 Study in NSCLC

April 12th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.

Dr. Garon on Sequencing of Agents for Advanced Lung Cancer

January 23rd 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing challenges for patients with advanced lung cancer.

Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

November 11th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

Dr. Garon on Differences Between Antiangiogenic Agents in Lung Cancer

September 8th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.

Dr. Garon on Antiangiogenic Agents in Lung Cancer

September 1st 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Dr. Garon on Future of Immunotherapy in NSCLC

July 6th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the future of immunotherapy in the paradigm of non–small cell lung cancer (NSCLC).

Dr. Garon on Concerns for Immunotherapy Combinations in Lung Cancer

October 24th 2016

Edward B. Garon, MD, director, Thoracic Oncology, Jonsson Comprehensive Cancer Center, UCLA, discusses his concerns for potential immunotherapy combinations for the treatment of patients with lung cancer.

Dr. Garon on Immunotherapy for Patients With NSCLC

August 5th 2016

Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer.